- $69.06bn
- $65.26bn
- $6.13bn
- 97
- 12
- 72
- 63
Annual income statement for Synopsys, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | R2022 October 31st | R2023 October 31st | 2024 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,685 | 4,204 | 4,616 | 5,318 | 6,127 |
Cost of Revenue | |||||
Gross Profit | 2,891 | 3,342 | 3,718 | 4,287 | 4,882 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,065 | 3,469 | 3,467 | 4,045 | 4,772 |
Operating Profit | 620 | 735 | 1,149 | 1,273 | 1,356 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 638 | 806 | 1,103 | 1,305 | 1,514 |
Provision for Income Taxes | |||||
Net Income After Taxes | 663 | 756 | 964 | 1,191 | 1,414 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 664 | 758 | 985 | 1,230 | 2,263 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 664 | 758 | 985 | 1,230 | 2,263 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.23 | 4.49 | 6.69 | 8.03 | 9.77 |